Abstract:Rationale LRPPRC (leucine‐rich pentatricopeptide repeat‐containing protein) is commonly described as a regulator of RNA metabolism in both mitochondria and nuclei, but the overall biological impact of this role remains unclear. Integrative genomics analyses have revealed that mutations in the LRPPRC gene were causing the cytochrome c oxidase defect in the French‐Canadian variant of Leigh Syndrome (LSFC) (Mootha et al. 2003). More recently, a targeted metabolomics study in LSFC patients highlighted specific markers reflecting mitochondrial metabolic perturbations for various nutrients including fatty acids (Thompson‐Legault et al. 2015). The role of LRPPRC in lipid metabolism remains, however, to be better deciphered. Goal & Methods To dissect the role of LRPPRC in lipid metabolism, we have analyzed plasma from LSFC patients as well as plasma and livers from hepato‐specific KO‐LRPPRC mice using a combination of mass spectrometry (MS)‐based approaches. These include: (1) an untargeted and comprehensive lipidomic workflow, which enables the coverage of > 1300 unique lipid entities, and (2) targeted lipidomic analyses to probe fatty acid (FA) metabolism through acylcarnitines (ACs) profiling (covering >100 species) or cholesterol catabolism into bile acids (BAs; 9 (un)conjugated species). Results The lipidomic profile observed in LSFC patients is typically characteristic of peroxisomal dysfunction as revealed by a: (i) 2‐fold decrease in plasmalogens (Pls; p<0.01), (ii) 2‐fold decrease in conjugate BAs such as glyco‐(G), glycodeoxy‐(GD) (p<0.001) and tauro‐(T) (p 20 carbons (p<0.05). These results in humans were corroborated in transgenic mice. Indeed, in plasma, there is a 1.5‐fold decrease in Pls (p<0.05). In addition, in liver, several results point out to a remodeling of peroxisomal metabolism. These include: (i) an imbalance in BA conjugation (10‐fold increase in CA, p<0.01; 1.4‐fold decrease in GDCA, p 20 carbons ACs (p<0.01). This notion is further substantiated by changes in gene and/or protein expression levels for: (i) catalase, a classical marker of peroxisome content (+16%; protein, p<0.001), (ii) ACOX1, marker of peroxisomal β‐oxidation (−40%; protein, p<0.05) and (iii) several peroxins (Pex) involved in peroxisome biogenesis and transport, namely Pex11β, Pex14, Pex19, Pex1 and Pex 10 (up to +60%; mRNA; p<0.05). Conclusion Collectively there results highlight a novel role for LRPPRC in the regulation of lipid metabolism beyond mitochondria, namely in peroxisomes. Whether peroxisomal lipid perturbations are specific to LRPPRC gene defect or represent a common feature of mitochondrial dysfunction remain, however, to be further ascertained. Support or Funding Information This work was supported by the “Fondation Grand défi Pierre Lavoie”.

Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC)

Abnormal morphology and function in retinal ganglion cells derived from patients-specific iPSCs generated from individuals with Leber's hereditary optic neuropathy.

Human iPSC-derived cerebral organoids model features of Leigh syndrome and reveal abnormal corticogenesis

Expression signature of the Leigh syndrome French-Canadian type

Abstract 58: Modeling Pathogenesis in Familial Hypertrophic Cardiomyopathy Using Patient-Specific Induced Pluripotent Stem Cells

Loss of hepatic LRPPRC alters mitochondrial bioenergetics, regulation of permeability transition and trans-membrane ROS diffusion

Defective metabolic programming impairs early neuronal morphogenesis in neural cultures and an organoid model of Leigh syndrome

Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses

Induced pluripotent stem cells derived from patients carrying mitochondrial mutations exhibit altered bioenergetics and aberrant differentiation potential

Disease models of Leigh syndrome: From yeast to organoids

Leigh Syndrome: A Study of 209 Patients at the Beijing Children's Hospital

Metabolic rescue ameliorates mitochondrial encephalo‐cardiomyopathy in murine and human iPSC models of Leigh syndrome

An Induced Pluripotent Stem Cell Model of Hypoplastic Left Heart Syndrome (HLHS) Reveals Multiple Expression and Functional Differences in HLHS-derived Cardiac Myocytes.

Nuclear Modifier YARS2 Allele Correction Restored Retinal Ganglion Cells-Specific Deficiencies in Leber’s Hereditary Optic Neuropathy

Unleashing the Power of Induced Pluripotent stem Cells in in vitro Modelling of Lesch-Nyhan Disease

643 Mutations in Cel and Hras1 Are Associated with Obesity-Associated Hepatocellular Carcinoma

Modeling of lung phenotype of Hermansky–Pudlak syndrome type I using patient-specific iPSCs

Unravelling a role of LRPPRC in peroxisomal lipid metabolism through lipidomic investigations in human and mouse

Human induced pluripotent stem cell line (FDHSi005-A) derived from a patient with a deep intronic variant in the GNE gene

Ndufs4 knockout mice with isolated complex I deficiency engage a futile adaptive brain response

Identification of a gene causing human cytochrome c oxidase deficiency by integrative genomics